JAZZ

Nov 02, 11:45 PMJazz posts Q3 2026 adjusted loss of $3.88 vs $4.09 expected, beats on $1.24B revenue, raises 2026 revenue guidance to $4.78–$4.85B

Peers: HRMY AXSM ALKS INCY EXEL NBIX BMRN CORT SUPN UTHR

| Held by: IJH VTI VB VBR VXF XMMO VFLO MDY IJK DFAT

Scroll to Statements

Index	-
Market Cap	14.99B
Enterprise Value	17.78B
Income	205.95M
Sales	4.72B
Book/sh	65.39
Cash/sh	44.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	2890
IPO	Jun 01, 2007

P/E	78.34
Forward P/E	8.68
PEG	0.18
P/S	3.18
P/B	3.53
P/C	5.25
P/FCF	9.24
EV/EBITDA	9.42
EV/Sales	3.77
Quick Ratio	1.64
Current Ratio	1.82
Debt/Eq	1.35
LT Debt/Eq	1.10
Option/Short	Yes / Yes

EPS (ttm)	2.95
EPS next Y	26.62
EPS next Q	6.95
EPS this Y	78.74%
EPS next Y	77.74%
EPS next 5Y	47.83%
EPS past 3/5Y	-17.69% -
Sales past 3/5Y	5.26% 12.54%
EPS Y/Y TTM	331.22%
Sales Y/Y TTM	13.48%
EPS Q/Q	-283.08%
Sales Q/Q	10.38%
Earnings	Nov 02 AMC
EPS/Sales Surpr.	3.98% 2.69%

Insider Own	3.94%
Insider Trans	-4.95%
Inst Own	101.37%
Inst Trans	-0.59%
ROA	1.76%
ROE	5.05%
ROIC	2.34%
Gross Margin	74.60%
Oper. Margin	24.77%
Profit Margin	4.37%
SMA20	7.85%
SMA50	0.12%
SMA200	6.36%
Trades

Shs Outstand	64.10M
Shs Float	62.36M
Short Float	9.40%
Short Ratio	6.50
Short Interest	5.86M
52W High	266.38 -13.30%
52W Low	128.80 79.32%
Volatility	2.46% 3.15%
ATR (14)	7.36
RSI (14)	60.26
Beta	0.37
Rel Volume	1.35
Avg Volume	901.42K
Volume	918,773

Perf Week	11.69%
Perf Month	-2.15%
Perf Quarter	-11.70%
Perf Half Y	8.81%
Perf YTD	35.86%
Perf Year	66.90%
Perf 3Y	74.89%
Perf 5Y	68.69%
Perf 10Y	138.74%
Recom	1.42
Target Price	299.29
Prev Close	214.44
Price	230.96
Change %	7.70%

Consensus

Strong Buy

Avg. Price Target

$299.29

Implied Upside

+29.6%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 30, 2026	Initiated	CCitigroup	Buy	$325	+40.7%
Sep 24, 2026	Resumed	GGoldman	Buy	$337	+45.9%
Jul 17, 2026	Initiated	CCanaccord Genuity	Buy	$290	+25.6%
Jun 09, 2026	Resumed	TTruist	Buy	$256	+10.8%
May 22, 2026	Initiated	BBernstein	Mkt Perform	$229	-0.8%
May 19, 2026	Upgrade	UUBS	Neutral → Buy	$307	+32.9%
Apr 10, 2026	Resumed	RRaymond James	Outperform	$227	-1.7%
Feb 27, 2026	Initiated	BBarclays	Overweight	$224	-3.0%
Nov 24, 2025	Downgrade	UUBS	Buy → Neutral	$188	-18.6%
Jul 15, 2025	Initiated	DDeutsche Bank	Buy	$152	-34.2%
Mar 07, 2025	Upgrade	UUBS	Neutral → Buy	$145 → $179	-22.5%
Feb 26, 2025	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Feb 13, 2025	Upgrade	WWells Fargo	Equal Weight → Overweight	$130 → $170	-26.4%
Dec 12, 2024	Upgrade	MMorgan Stanley	Equal-Weight → Overweight	$140 → $175	-24.2%
Jun 05, 2024	Initiated	GGoldman	Buy	$169	-26.8%
Jan 03, 2024	Initiated	RRobert W. Baird	Outperform	$160	-30.7%
Nov 27, 2023	Downgrade	UUBS	Buy → Neutral	$170 → $135	-41.5%
Sep 29, 2023	Initiated	RRaymond James	Mkt Perform
Jun 12, 2023	Resumed	WWells Fargo	Equal Weight	$184 → $140	-39.4%
Dec 09, 2022	Upgrade	GGoldman	Neutral → Buy	$192 → $190	-17.7%

Today 11:36AM	4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research) +7.70%
Nov-02-26 11:29PM	Jazz: Q3 Earnings Snapshot (Associated Press)
06:40PM	Jazz Pharmaceuticals Beats As Revenue Guidance Rises Again, But Slowing Growth And An Actio Charge Leave The Stock At A Crossroads (Earnings Whispers)
04:05PM	Jazz Pharmaceuticals Announces Third Quarter 2026 Financial Results (PR Newswire)
08:30AM	Jazz Pharmaceuticals to Highlight Neuro-Oncology Clinical Research at SNO 2026 (PR Newswire)
06:30AM	Loading…
Oct-30-26 06:30AM	With Setara, the team behind Actio opens its second act (BioPharma Dive)
Oct-26-26 12:48PM	Jazz Must Prove Its Xywav Surge Is Durable After A Raise The Market Has Shrugged Off (Earnings Whispers)
Oct-23-26 10:15AM	Ziihera (zanidatamab-hrii) Combinations Demonstrate Sustained Survival at Three Years in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma at ESMO 2026 (PR Newswire)
Oct-19-26 04:15PM	Jazz Pharmaceuticals to Report Third Quarter Financial Results on November 2, 2026 (PR Newswire)
Oct-15-26 01:38PM	Cathie Wood-Backed Biotech IPO Pops in Debut (Barrons.com)
Oct-07-26 09:48AM	Former Gilead and Amgen Commercial Leader Laura Hamill Just Joined Entera (NASDAQ: ENTX) (FinanceWire)
Sep-30-26 09:40AM	Target upgraded, Moderna downgraded: Wall Street's top analyst calls (The Fly)
Sep-15-26 09:00AM	Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences (PR Newswire)
Sep-08-26 01:28PM	Quoin in line for second priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
01:28PM	Quoin in line for priority review voucher if rare paediatric drug approved (Pharmaceutical Technology)
04:15PM	Loading…
Sep-02-26 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
Sep-01-26 04:48PM	Duncan Ferguson Joins Neovii Pharmaceuticals AG to Lead Global Commercial Expansion as Chief Commercial Officer (NewMediaWire)
Aug-31-26 06:00AM	Ziihera (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA (PR Newswire)
Aug-27-26 12:30AM	Jazz Pharmaceuticals Announces Pricing of Upsized Private Offering of $1.1 Billion of 1.875% Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases (PR Newswire)
Aug-26-26 07:00AM	Jazz Pharmaceuticals Announces Private Offering of $1.0 Billion of Exchangeable Senior Notes due 2032 and Concurrent Ordinary Share Repurchases (PR Newswire)
Aug-25-26 01:21PM	New Jazz cancer drug approval could drive blockbuster sales (BioPharma Dive)
12:26PM	JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy (Stocktwits)
11:01AM	Jazz Pharmaceuticals Wins FDA Approval for Ziihera Regimens in First-Line HER2+ Advanced GEA (InvestorsHub)
10:00AM	U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma (PR Newswire)
Aug-24-26 06:48AM	Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab (InvestorsHub)
Aug-11-26 05:43AM	Jazz Pharmaceuticals to acquire Actio Biosciences for $820m upfront (Pharmaceutical Business Review)
Aug-10-26 07:36AM	Jazz to buy rare epilepsy drugmaker in potentially $1.3B deal (BioPharma Dive)
07:30AM	Jazz Pharmaceuticals to Acquire Actio Biosciences, Expanding Rare Epilepsy Portfolio (PR Newswire)
Aug-06-26 01:01AM	AbCellera Biologics Inc (ABCL) (Q2 2026) Earnings Call Highlights: Strong Pipeline Progress and ... (GuruFocus.com)
Aug-04-26 01:07AM	Jazz Pharmaceuticals PLC (JAZZ) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ... (GuruFocus.com)
04:51PM	Loading…
Aug-03-26 04:51PM	Jazz: Q2 Earnings Snapshot (Associated Press)
04:05PM	Jazz Pharmaceuticals Announces Second Quarter 2026 Financial Results (PR Newswire)
Jul-20-26 04:15PM	Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 3, 2026 (PR Newswire)
Jul-17-26 09:41AM	Apple upgraded, Brinker initiated: Wall Street's top analyst calls (The Fly)
Jul-01-26 03:45PM	Why VERAXA Biotech (VRXA) Shareholders Should Pay Serious Attention to Antibody Therapeutics Sector Deals (NewMediaWire)
Jun-28-26 11:56PM	Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? (Stocktwits)
Jun-18-26 06:33AM	Jazz and AbCellera sign deal for T-cell engagers in solid tumours (Pharmaceutical Technology)
Jun-17-26 08:50AM	Jazz Pharmaceuticals and AbCellera Partner on Antibody Programs for Solid Tumors (InvestorsHub)
07:00AM	Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies (PR Newswire)
Jun-16-26 04:05PM	Jazz Pharmaceuticals Delivers Extensive Late-Breaking Data at SLEEP 2026, Demonstrating Real-World Impact of Xywav (calcium, magnesium, potassium, and sodium oxybates) on Patient Outcomes Across Narcolepsy and Idiopathic Hypersomnia (PR Newswire)
Jun-12-26 08:00AM	Jazz Pharmaceuticals Provides Update on Zepzelca (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer (PR Newswire)
Jun-04-26 07:45AM	Jazz Pharmaceuticals to Present Comprehensive Data at SLEEP 2026 Highlighting Broad Treatment Effects of Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for People with Narcolepsy and Idiopathic Hypersomnia (PR Newswire)
May-28-26 04:27PM	JPMorgan says large-cap biotech is back as profits and pipelines fuel upside (Investing.com)
May-27-26 05:00PM	Phase 3 HERIZON-GEA-01 Results Published in The New England Journal of Medicine Show Durable and Consistent Survival Benefit with Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA (PR Newswire)
May-22-26 09:38AM	Texas Instruments, Generac upgraded: Wall Street's top analyst calls (The Fly)
May-19-26 09:34AM	StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls (The Fly)
May-12-26 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
May-05-26 04:31PM	Jazz: Q1 Earnings Snapshot (Associated Press) +7.68%
04:05PM	Jazz Pharmaceuticals Announces First Quarter 2026 Financial Results (PR Newswire)
Apr-27-26 07:45AM	Jazz Pharmaceuticals Announces FDA Acceptance and Priority Review of Supplemental Biologics License Application for Ziihera (zanidatamab-hrii) Combinations in First-Line HER2+ Locally Advanced or Metastatic GEA (PR Newswire)
Apr-21-26 04:15PM	Jazz Pharmaceuticals to Report First Quarter Financial Results on May 5, 2026 (PR Newswire)
04:05PM	Jazz Pharmaceuticals to Present Data at ASCO 2026 Highlighting Advancements for Ziihera (zanidatamab-hrii) in Gastroesophageal Adenocarcinoma and Zepzelca (lurbinectedin) (PR Newswire)
Apr-10-26 09:37AM	Nike downgraded, IBM initiated: Wall Street's top analyst calls (The Fly)
Apr-09-26 07:45AM	Jazz Pharmaceuticals to Present Research on Epidiolex (cannabidiol) and Xywav (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting (PR Newswire)
Apr-01-26 04:15PM	Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference (PR Newswire)
Mar-24-26 01:49PM	American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education (PR Newswire)
Mar-18-26 07:44AM	Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 (PR Newswire)
Mar-09-26 11:40AM	JAZZ or ACAD: Which Is the Better Value Stock Right Now? (Zacks)
Mar-06-26 03:17PM	Taco Bell Parent, Data Center Play And Two Other Stocks Weather War Storm, Hover Near Highs (Investor's Business Daily)
Mar-05-26 08:02PM	Saniona AB (FRA:30S) Q4 2025 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
Mar-03-26 03:24PM	Jazz Pharmaceuticals plc (JAZZ) Reports $1.2 Billion Q4 Revenue, Beats $1.17B Estimate (Insider Monkey)
Mar-02-26 10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
09:15AM	Jazz (JAZZ) Reliance on International Sales: What Investors Need to Know (Zacks)
Mar-01-26 04:27AM	Is Jazz Pharmaceuticals (JAZZ) One of the Best Cheap Biotech Stocks to Buy Now? (Insider Monkey)
Feb-27-26 09:54AM	Jazz Pharmaceuticals' CBD Drug Hits $1B: Time to Buy the Stock? (Zacks)
08:51AM	Jazz Pharmaceuticals plc (JAZZ) Jumps Nearly 30% on Strong Q3 and Cancer Drug Trial Progress (Insider Monkey)
07:59AM	Here Are Fridays Top Wall Street Analyst Research Calls: Block, Costco, Dollar Tree, Duolingo, Palantir Technologies, Southwest Airlines, Synopsis, Warner Bros. Discovery, and More (24/7 Wall St.)
Feb-26-26 07:55AM	Company News for Feb 26, 2026 (Zacks)
Feb-25-26 07:55PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research) +13.23%
03:51PM	Jazz Pharmaceuticals (JAZZ) Stock Trades Up, Here Is Why (StockStory)
12:49PM	Stock Market Today: Nasdaq, Dow Hold Gains Before Nvidia Earnings; Vertiv, Keysight Advance (Live Coverage) (Investor's Business Daily)
11:19AM	Stock Market Today: Dow Advance Melts Before Nvidia Earnings; Missile Firm L3Harris Eyes Entry (Live Coverage) (Investor's Business Daily)
10:56AM	JAZZ Stock Rises as Q4 Earnings & Sales Top Expectations (Zacks)
10:24AM	Stock Market Today: Dow Up 100 Points Before Nvidia Earnings; This Drug Firm Breaks Out (Live Coverage) (Investor's Business Daily)
12:08AM	Jazz Pharmaceuticals Q4 Earnings Call Highlights (MarketBeat)
12:04AM	Jazz Pharmaceuticals PLC (JAZZ) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... (GuruFocus.com)
Feb-24-26 08:00PM	Jazz (JAZZ) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
07:30PM	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks)
04:30PM	Jazz: Q4 Earnings Snapshot (Associated Press Finance)
04:20PM	Jazz Pharmaceuticals (NASDAQ:JAZZ) Surprises With Q4 CY2025 Sales (StockStory)
12:08PM	AXSM Q4 Loss Wider Than Expected, Revenues Surge Y/Y on Auvelity Sales (Zacks)
Feb-23-26 07:03PM	Analyst Report: Jazz Pharmaceuticals plc (Morningstar Research)
Feb-22-26 10:10PM	Jazz Pharmaceuticals Earnings: What To Look For From JAZZ (StockStory)
Feb-19-26 09:15AM	What Analyst Projections for Key Metrics Reveal About Jazz (JAZZ) Q4 Earnings (Zacks)
Feb-18-26 10:00AM	Arcutis Biotherapeutics, Inc. (ARQT) Earnings Expected to Grow: Should You Buy? (Zacks)
08:36AM	Ovintiv to Report Q4 Earnings: What's in Store for the Stock? (Zacks)
Feb-17-26 04:15PM	Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences (PR Newswire)
10:00AM	Jazz Pharmaceuticals (JAZZ) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Feb-11-26 08:36AM	Is the Options Market Predicting a Spike in Jazz Pharmaceuticals Stock? (Zacks)
Feb-10-26 04:15PM	Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 (PR Newswire)
Feb-09-26 07:51AM	Moderna to Report Q4 Earnings: Is a Beat in Store for the Stock? (Zacks)
Feb-03-26 07:56AM	New Drugs Take Center Stage as Biogen Heads Into Q4 Earnings (Zacks)
06:55AM	Truist Securities Raises Jazz Pharmaceuticals (JAZZ) Price Target After HERIZON-GEA Trial (Insider Monkey)
Jan-30-26 12:39PM	This Pharma Stock Eyes Entries, Battles For Key Level Amid 68% Earnings Growth (Investor's Business Daily)
Jan-27-26 12:22PM	Harmony Biosciences' Sales and Profits Have Soared. Why Hasn't Its Stock Followed? (Motley Fool)
Jan-26-26 10:15AM	Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026? (Zacks)
Jan-16-26 06:24AM	Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading (BioPharma Dive)
Jan-15-26 12:41PM	JPM26: Jazz sells PRV for $200m, targets deals in 2026 (Pharmaceutical Technology)
Jan-13-26 07:43AM	Jazz Pharmaceuticals price target raised to $235 from $210 at Needham (TipRanks)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bruce C Cozadd	Officer	Nov 02 '26	Proposed Sale	215.84	6,000	1,295,040		Nov 02 04:27 PM
ANNE O'RIORDAN	Director	Oct 08 '26	Proposed Sale	228.55	14,687	3,356,714		Oct 08 04:04 PM
GALA RENEE D	President & CEO	Oct 06 '26	Sale	236.40	2,000	472,800	141,394	Oct 07 05:44 PM
RENEE D GALA	Officer	Oct 06 '26	Proposed Sale	236.40	2,000	472,800		Oct 06 04:20 PM
COZADD BRUCE C	Director	Oct 01 '26	Sale	230.33	6,000	1,381,980	345,875	Oct 05 04:18 PM
Bruce C Cozadd	Officer	Oct 01 '26	Proposed Sale	230.33	6,000	1,381,980		Oct 01 04:32 PM
Patil Neena M	EVP & Chief Legal Officer	Sep 10 '26	Sale	240.94	1,200	289,128	47,671	Sep 14 06:38 PM
GALA RENEE D	President & CEO	Sep 08 '26	Sale	243.03	2,000	486,060	143,394	Sep 10 04:33 PM
NEENA PATIL	Officer	Sep 10 '26	Proposed Sale	240.94	1,200	289,128		Sep 10 04:06 PM
RENEE D GALA	Officer	Sep 08 '26	Proposed Sale	243.03	2,000	486,060		Sep 08 04:37 PM
Henderson Mary Elizabeth	Director	Sep 08 '26	Proposed Sale	246.81	2,691	664,166		Sep 08 02:27 PM
COZADD BRUCE C	Director	Sep 01 '26	Sale	250.13	6,000	1,500,780	351,875	Sep 02 05:03 PM
Bruce C Cozadd	Officer	Sep 01 '26	Proposed Sale	250.13	6,000	1,500,780		Sep 01 04:21 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Aug 27 '26	Option Exercise	125.84	57,500	7,235,860	142,607	Aug 31 06:45 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Aug 27 '26	Sale	249.70	76,921	19,207,098	65,686	Aug 31 06:45 PM
LOVE TED W	Director	Aug 31 '26	Proposed Sale	244.54	1,527	373,413		Aug 31 05:04 PM
Winningham Rick E	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 04:51 PM
Kennedy Patrick	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 04:42 PM
ENRIGHT PATRICK G	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 04:33 PM
RIEDEL NORBERT G	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 04:22 PM
Smith Mark Douglas	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 04:14 PM
Henderson Mary Elizabeth	Director	Aug 31 '26	Proposed Sale	244.54	3,852	941,968		Aug 31 03:50 PM
Hamill Laura	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 03:41 PM
Cook Jennifer E.	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 03:36 PM
McSharry Heather Ann	Director	Aug 31 '26	Proposed Sale	244.54	3,507	857,602		Aug 31 03:26 PM
COZADD BRUCE C	Director	Aug 31 '26	Proposed Sale	244.54	2,506	612,817		Aug 31 03:10 PM
ROBERT IANNONE	Officer	Aug 27 '26	Proposed Sale	249.70	76,921	19,207,100		Aug 27 04:31 PM
ORiordan Anne	Director	Aug 07 '26	Proposed Sale	251.58	3,507	882,291		Aug 07 02:09 PM
COZADD BRUCE C	Director	Aug 03 '26	Sale	252.98	6,000	1,517,880	360,682	Aug 05 04:33 PM
Bruce C Cozadd	Officer	Aug 03 '26	Proposed Sale	252.98	6,000	1,517,880		Aug 03 04:16 PM
COZADD BRUCE C	Director	Jul 01 '26	Sale	240.47	6,000	1,442,820	366,682	Jul 06 06:23 PM
Bruce C Cozadd	Officer	Jul 01 '26	Proposed Sale	240.47	6,000	1,442,820		Jul 01 03:55 PM
Smith Mark Douglas	Director	Jun 15 '26	Sale	230.55	1,157	266,746	9,680	Jun 17 04:45 PM
MARK D SMITH	Director	Jun 15 '26	Proposed Sale	230.55	1,157	266,746		Jun 15 04:09 PM
Patil Neena M	EVP & Chief Legal Officer	Jun 10 '26	Sale	231.83	1,200	278,196	51,549	Jun 12 04:14 PM
NEENA PATIL	Officer	Jun 10 '26	Proposed Sale	231.83	1,200	278,196		Jun 10 04:04 PM
COZADD BRUCE C	Director	Jun 01 '26	Sale	235.12	6,000	1,410,720	372,682	Jun 03 05:09 PM
Bruce C Cozadd	Officer	Jun 01 '26	Proposed Sale	235.12	6,000	1,410,720		Jun 01 04:13 PM
Patil Neena M	EVP & Chief Legal Officer	May 28 '26	Sale	236.97	1,192	282,468	52,626	Jun 01 04:09 PM
Pearce Samantha	EVP, Chief Commercial Officer	May 28 '26	Option Exercise	109.45	6,907	755,971	57,179	Jun 01 04:06 PM
Pearce Samantha	EVP, Chief Commercial Officer	May 28 '26	Sale	235.41	6,907	1,625,977	50,272	Jun 01 04:06 PM
Mulligan Seamus	Director	May 28 '26	Option Exercise	138.08	3,415	471,543	1,183,028	Jun 01 04:01 PM
NEENA PATIL	Officer	May 28 '26	Proposed Sale	236.97	1,192	282,468		May 28 04:21 PM
SAMANTHA PEARCE	Officer	May 28 '26	Proposed Sale	235.41	6,907	1,625,977		May 28 04:18 PM
Winningham Rick E	Director	May 22 '26	Option Exercise	138.08	3,415	471,543	12,308	May 27 06:13 PM
Winningham Rick E	Director	May 22 '26	Sale	241.57	2,741	662,143	9,567	May 27 06:13 PM
McSharry Heather Ann	Director	May 22 '26	Sale	241.00	2,000	482,000	18,449	May 27 06:07 PM
HEATHER MCSHARRY	Director	May 22 '26	Proposed Sale	241.00	2,000	482,000		May 22 04:27 PM
RICK WINNINGHAM	Director	May 22 '26	Proposed Sale	241.57	2,741	662,143		May 22 04:13 PM
COZADD BRUCE C	Director	May 01 '26	Sale	203.33	6,000	1,219,980	378,682	May 05 04:27 PM
Bruce C Cozadd	Officer	May 01 '26	Proposed Sale	203.33	6,000	1,219,980		May 01 03:44 PM
COZADD BRUCE C	Director	Apr 01 '26	Sale	190.50	6,000	1,143,010	384,682	Apr 03 05:09 PM
Bruce C Cozadd	Officer	Apr 01 '26	Proposed Sale	190.50	6,000	1,143,010		Apr 01 04:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Mar 09 '26	Sale	182.94	1,287	235,444	6,512	Mar 09 05:15 PM
PATRICIA CARR	Officer	Mar 09 '26	Proposed Sale	182.94	1,287	235,444		Mar 09 04:26 PM
Carr Patricia	Officer	Mar 05 '26	Proposed Sale	188.69	2,723	513,803		Mar 05 02:48 PM
Henderson Mary Elizabeth	Officer	Feb 26 '26	Proposed Sale	188.69	2,643	498,708		Mar 05 01:58 PM
COZADD BRUCE C	Director	Mar 03 '26	Sale	186.44	6,000	1,118,613	405,796	Mar 04 04:24 PM
Bruce C Cozadd	Officer	Mar 03 '26	Proposed Sale	186.44	6,000	1,118,613		Mar 03 02:35 PM
RIEDEL NORBERT G	Director	Feb 27 '26	Option Exercise	138.08	3,415	471,543	10,439	Mar 02 05:36 PM
RIEDEL NORBERT G	Director	Feb 27 '26	Sale	192.00	3,415	655,680	7,024	Mar 02 05:36 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 26 '26	Sale	194.11	1,253	243,222	10,352	Mar 02 05:14 PM
Carr Patricia	SVP, Chief Accounting Officer	Feb 27 '26	Sale	190.91	1,117	213,243	9,235	Mar 02 05:14 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 26 '26	Option Exercise	127.23	51,000	6,488,700	83,946	Mar 02 05:06 PM
Patil Neena M	EVP & Chief Legal Officer	Feb 26 '26	Sale	191.56	55,600	10,650,482	56,862	Mar 02 05:06 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Feb 26 '26	Sale	194.49	5,343	1,039,134	28,728	Mar 02 05:04 PM
PATRICIA CARR	Officer	Feb 27 '26	Proposed Sale	190.91	1,117	213,243		Feb 27 04:22 PM
NORBERT RIEDEL	Director	Feb 27 '26	Proposed Sale	192.00	3,415	655,680		Feb 27 04:12 PM
NEENA PATIL	Officer	Feb 26 '26	Proposed Sale	191.56	55,600	10,650,480		Feb 26 04:14 PM
Carr Patricia	Officer	Feb 26 '26	Proposed Sale	196.83	2,370	466,487		Feb 26 04:08 PM
Henderson Mary Elizabeth	Officer	Feb 26 '26	Proposed Sale	196.83	10,116	1,991,132		Feb 26 03:48 PM
Henderson Mary Elizabeth	SVP, Technical Operations	Dec 09 '25	Sale	169.51	2,238	379,366	19,508	Dec 11 05:19 PM
MARY ELIZABETH HENDERSON	Officer	Dec 09 '25	Proposed Sale	169.51	2,238	379,365		Dec 09 06:52 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Option Exercise	140.67	4,500	633,015	11,512	Dec 09 05:25 PM
Carr Patricia	SVP, Chief Accounting Officer	Dec 05 '25	Sale	171.20	4,660	797,783	7,012	Dec 09 05:25 PM
PATRICIA CARR	Officer	Dec 05 '25	Proposed Sale	171.20	4,660	797,783		Dec 05 04:03 PM
O'Keefe Kenneth W	Director	Dec 02 '25	Proposed Sale	176.59	1,249	220,561		Dec 01 08:55 PM
COZADD BRUCE C	Director	Nov 26 '25	Option Exercise	123.36	77,500	9,560,400	470,832	Dec 01 06:14 PM
COZADD BRUCE C	Director	Nov 26 '25	Sale	177.81	77,500	13,780,337	393,332	Dec 01 06:14 PM
BRUCE COZADD	Director	Nov 26 '25	Proposed Sale	177.81	77,500	13,780,337		Nov 26 05:37 PM
McSharry Heather Ann	Director	Nov 20 '25	Option Exercise	138.08	3,415	471,543	23,864	Nov 24 05:47 PM
McSharry Heather Ann	Director	Nov 20 '25	Sale	177.78	3,415	607,127	20,449	Nov 24 05:47 PM
COZADD BRUCE C	Director	Nov 18 '25	Sale	181.09	18,000	3,259,538	390,826	Nov 20 08:03 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Option Exercise	136.18	5,250	714,945	12,262	Nov 20 06:13 PM
Carr Patricia	SVP, Chief Accounting Officer	Nov 18 '25	Sale	182.06	5,319	968,402	7,012	Nov 20 06:13 PM
Winningham Rick E	Director	Nov 18 '25	Sale	180.86	5,500	994,728	8,893	Nov 20 05:54 PM
HEATHER MCSHARRY	Director	Nov 20 '25	Proposed Sale	177.78	3,415	607,127		Nov 20 04:05 PM
Henderson Mary Elizabeth	Officer	Nov 19 '25	Proposed Sale	127.23	2,961	376,740		Nov 19 08:59 PM
Iannone Robert	EVP, Global Head of R&D & CMO	Nov 17 '25	Sale	168.26	7,159	1,204,573	72,628	Nov 19 08:31 PM
Bruce C Cozadd	Officer	Nov 18 '25	Proposed Sale	181.09	18,000	3,259,537		Nov 18 07:08 PM
RICK WINNINGHAM	Director	Nov 18 '25	Proposed Sale	180.86	5,500	994,728		Nov 18 05:20 PM
PATRICIA CARR	Officer	Nov 18 '25	Proposed Sale	182.06	5,319	968,402		Nov 18 04:59 PM
ROBERT IANNONE	Officer	Nov 17 '25	Proposed Sale	168.26	7,159	1,204,573		Nov 17 04:06 PM

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Co-Founder & ChairmanMr. Bruce C. Cozadd

PresidentMs. Renee D. Gala

Executive VP & CFOMr. Philip L. Johnson

Executive VP & Chief Legal OfficerMs. Neena M. Patil J.D.

Executive VPDr. Robert Iannone M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Jazz Pharmaceuticals plc

Upgrade your Finviz experience